Ex-NBA star Earl 'The Pearl' greets urologists in Atlanta

NBA Hall of Famer Earl "The Pearl" Monroe meets Manhattan urologistRobert Salant, MD, at the Boehringer Ingelheim Pharmaceuticalsbooth yesterday. Monroe is a spokesman for the company's BPHproduct, tamsulosin (Flomax). Known for his free-flowing finesse onthe court, Monroe was a four-time All-Star and was named to the NBA50th Anniversary All-Time Team. He is currently a sportscommentator.

NBA Hall of Famer Earl "The Pearl" Monroe meets Manhattan urologist Robert Salant, MD, at the Boehringer Ingelheim Pharmaceuticals booth yesterday. Monroe is a spokesman for the company's BPH product, tamsulosin (Flomax). Known for his free-flowing finesse on the court, Monroe was a four-time All-Star and was named to the NBA 50th Anniversary All-Time Team. He is currently a sports commentator.

Related Videos

Related Content

Advertisement

December 6th 2024

Gemcitabine-BCG shows early promise in BCG-exposed NMIBC

Benjamin P. Saylor

CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 6th 2024

SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

Benjamin P. Saylor

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 5th 2024

BOND-003: Cretostimogene yields high CR rate, is well tolerated in NMIBC

Benjamin P. Saylor Hannah Clarke

The overall complete response rate was 74.5% (95% CI, 65.4%-82.4%).

December 5th 2024

Investigators characterize safety profile of belzutifan in advanced RCC

Benjamin P. Saylor

Anemia was the most frequently observed any-cause AE and was seen in 485 (84.2%) patients.

Related Content

Advertisement

December 6th 2024

Gemcitabine-BCG shows early promise in BCG-exposed NMIBC

Benjamin P. Saylor

CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 6th 2024

SunRISe-1 data point to safety, tolerability of TAR-200 in NMIBC

Benjamin P. Saylor

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 5th 2024

BOND-003: Cretostimogene yields high CR rate, is well tolerated in NMIBC

Benjamin P. Saylor Hannah Clarke

The overall complete response rate was 74.5% (95% CI, 65.4%-82.4%).

December 5th 2024

Investigators characterize safety profile of belzutifan in advanced RCC

Benjamin P. Saylor

Anemia was the most frequently observed any-cause AE and was seen in 485 (84.2%) patients.